With more than 6,000 rare diseases recognized by the NIH, the market for orphan and ultra-orphan indications represents a major growth area for pharma and biotech companies. But low patient numbers combined with the urgency of unmet medical needs can make standard clinical trial procedures unfeasible.
ExL Pharma's 2nd Rare Disease Collaboration Summit gives you the tools you need to build lasting partnerships with patient advocacy groups in order to construct more flexible and patient-centric clinical trial protocols and accelerate the regulatory approval of your orphan drug.
This event hosts the formation of working group relationships that harness the collective resources of industry and patient advocates, creating a working framework for shaping legislation and convincing regulators. Build best practice outputs that outlive the meeting.
Conference Only - Early Bird Price prior to June. 5, 2015: USD 1895.00
Conference Only - Standard Rate after June 5, 2015: USD 2095
Speakers: Gail Adinamis, Globalcare Clinical Trials, LTD, Rino Aldrighetti, Pulmonary Hypertension Association, Ronald Bartek, Friedreich's Ataxia Research Alliance (FARA), Diane Berry, Sarepta Therapeutics, PJ Brooks, NCATS/NIH, Ted Buckley, Shire, Carrie Burke, Shire, Nina DiPrimio, Perlstein Lab, Pat Furlong, Parent Project Muscular Dystrophy (PPMD), Brett Kopelan, NORD, Catie Olson, Stanford University School of Medicine, Deborah O'Neil, NovaBiotics Ltd, Liz Ottinger, Therapeutics for Rare and Neglected Disease, Kari Rosbeck, Tuberous Sclerosis Alliance, Kyra Rosow, Pfizer, Inc., Yaffa Rubinstein, Office of Rare Diseases Research, NIH, Daniel Ward, Pfizer, Inc., Elizabeth White, Pfizer, Inc., Nora Yang, NIH Therapeutics for Rare and Neglected Diseases
Sign in to add slides, notes or videos to this session